8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial
In a triple-blind, placebo-controlled crossover trial, 51 hypertensive patients received either celery seed capsules (1.34 g extract daily) or placebo for 4 weeks alongside usual medications. Celery seed extract was safe, reduced blood pressure, and decreased FBS from 108.53 to 97.96 mg/dL (p < 0.01). Significant reductions were seen in BUN (3.43 mg/dL), SCr (0.075 mg/dL), SGPT (4.08 U/L), SGOT (3.03 U/L), TC (16.37 mg/dL), TG (16.22 mg/dL), and LDL (11.84 mg/dL), along with an increase in HDL of 2.52 mg/dL (all p < 0.05 or p < 0.001). No significant changes were found in blood cells or serum electrolytes; the study was limited by a small sample size.
Shayani Rad M, Moohebati M, MohammadEbrahimi S, et al. Inflammopharmacology, 2022. PMID 35536382
2022 / Uncontrolled interventional program evaluation
Participants enrolled in a 15-day Jumpstart program were instructed to consume an Esselstyn-compliant, whole-food plant-based diet of vegetables, fruits, whole grains, and legumes. Among 389 participants, average weight loss was 5.8 pounds (7.3 for BMI >30), systolic blood pressure dropped by 6.8 points (16.8 for baseline >140), cholesterol decreased by 26 points (44 for baseline >200), LDL dropped by 19 points (33 for baseline >100), and fasting blood sugar fell by 5.1 points (28.4 for those starting in the diabetic range). All reported comparisons achieved statistical significance (P < .005 for fasting blood sugar and P < .001 for all others).
Friedman SM, Barnett CH, Franki R, et al. Am J Lifestyle Med, 2022. PMID 35706593
2021 / Randomized crossover trial
In a randomized crossover trial, healthy adults consumed 100 grams of bread paired with 250 milliliters of water, black tea, or lemon juice. Lemon juice reduced peak blood glucose concentration by 30% on average (p < 0.01) and delayed this peak by over 35 minutes (78 versus 41 minutes with water, p < 0.0001). Black tea had no effect on glycemic response, and neither beverage altered subsequent ad libitum energy intake.
Freitas D, Boué F, Benallaoua M, et al. Eur J Nutr, 2021. PMID 32201919
2021 / Randomized controlled trial
In the DIRECT PLUS trial, participants lost weight over 6 months on healthy guidelines, a Mediterranean diet, or a green-Mediterranean diet. Ninety participants provided fecal samples collected at month 6 and were randomized to receive capsules containing their own fecal microbiota (aFMT) or placebo until month 14. Across all participants, aFMT did not significantly reduce weight regain versus placebo (30.4% vs 40.6%, P = .28), but it significantly attenuated regain in the green-Mediterranean group (17.1% vs 50%, P = .02; P for interaction = .03). In this group, aFMT also reduced waist circumference gain (1.89 cm vs 5.05 cm, P = .01) and insulin rebound (P = .04).
Rinott E, Youngster I, Yaskolka Meir A, et al. Gastroenterology, 2021. PMID 32860791
2021 / Randomized, double-blind, placebo-controlled crossover trial
In a 24-month crossover trial, 125 postmenopausal women aged 45-85 years took 75 mg trans-resveratrol or placebo twice daily for 12 months, followed by the alternative treatment for 12 months. Compared to placebo, resveratrol resulted in a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Resveratrol also improved resting mean cerebral blood flow velocity (d = 0.275, P = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, P = 0.027) and cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025), and insulin resistance index (d = 0.102, P = 0.034). Women aged 65 and older showed a relative improvement in verbal memory compared to those younger than 65 years.
Thaung Zaw JJ, Howe PR, Wong RH Clin Nutr, 2021. PMID 32900519
2021 / Three-group randomized crossover trial
In a randomized crossover study, 60 men (with type 2 diabetes, overweight/obese, or healthy controls) consumed an energy- and macronutrient-matched vegan meal (V-meal) or conventional meat meal (M-meal). Thalamus perfusion decreased significantly after the M-meal in men with type 2 diabetes (p = 0.04) and overweight/obese men (p = 0.004), but decreased significantly after the V-meal in healthy controls (p < 0.001). Postprandial active GLP-1 secretion was higher after the V-meal compared with the M-meal by 42% in men with type 2 diabetes (p = 0.003) and by 41% in healthy controls (p = 0.002). Changes in thalamus perfusion after the meals correlated with changes in satiety (r = +0.68; p < 0.01).
Kahleova H, Tintera J, Thieme L, et al. Clin Nutr, 2021. PMID 33081982
2021 / Randomized, double-blind, placebo-controlled crossover trial
A randomized, double-blind, placebo-controlled crossover trial evaluated 12 weeks of once-daily oral semaglutide versus placebo in 15 subjects with type 2 diabetes. In 13 evaluable subjects, total daily ad libitum energy intake was significantly lower by 38.9% with oral semaglutide versus placebo (estimated treatment difference: -5096.0 kJ; 95% CI -7000.0, -3192.1; P = .0001). Satiety, hunger, and overall appetite scores significantly favored semaglutide after a fat-rich breakfast, alongside fewer food cravings and better eating control. Mean body weight decreased by 2.7 kg with oral semaglutide compared to 0.1 kg with placebo, primarily due to loss of body fat mass.
Gibbons C, Blundell J, Tetens Hoff S, et al. Diabetes Obes Metab, 2021. PMID 33184979
2021 / Randomized controlled trial
A randomized controlled trial assigned 48 obese women with PCOS to receive a low-calorie diet with either 5 g/day thylakoid-rich spinach extract or 5 g/day placebo for 12 weeks. Compared to placebo, the spinach extract group had a greater increase in serum omentin-1 (10.90 vs. 3.87 ng/L; p < .001) and greater reductions in fat mass (-5.19 vs. -1.35 kg; p < .001), neopterin (-0.66 vs. -0.38 nmol/L; p = .003), and chemerin (-41.24 vs. -11.26 ng/L; p < .001). Significant decreases in other anthropometric indices and insulin resistance were also observed in the thylakoid group compared to placebo (p < .001 for all parameters).
Pourteymour Fard Tabrizi F, Abbasalizad Farhangi M, Vaezi M, et al. Phytother Res, 2021. PMID 33368745
2021 / Double-blinded, placebo-controlled, randomized crossover trial
In a double-blind, placebo-controlled crossover study, 15 participants with type 2 diabetes underwent two 14-day treatment periods with acarbose or placebo. At the end of each period, participants underwent liquid mixed meal tests with concomitant infusion of the GLP-1 receptor antagonist exendin(9-39)NH2 or saline. Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. While no absolute difference was observed in exendin(9-39)NH2-induced glucose excursions between periods, postprandial glucose relatively increased by 119 ± 116% during exendin(9-39)NH2 infusion in the acarbose period versus 39 ± 27% in the placebo period (P = 0.0163).
Dalsgaard NB, Gasbjerg LS, Hansen LS, et al. Eur J Endocrinol, 2021. PMID 33449919
2021 / Randomized, double-blind, double-dummy, placebo-controlled trial
In this 68-week trial, 1210 adults with type 2 diabetes and a BMI of at least 27 kg/m2 were randomized to receive weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, alongside a lifestyle intervention. Estimated mean bodyweight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (difference -6.2 percentage points, 95% CI -7.3 to -5.2; p<0.0001). Significantly more patients taking semaglutide 2.4 mg achieved at least 5% weight reduction compared to placebo (68.8% vs 28.5%; OR 4.88, 95% CI 3.58 to 6.64; p<0.0001). Adverse events, particularly gastrointestinal events, were more common with semaglutide 2.4 mg (87.6% total, 63.5% gastrointestinal) than with placebo (76.9% total, 34.3% gastrointestinal).
Davies M, Færch L, Jeppesen OK, et al. Lancet, 2021. PMID 33667417
2021 / 10-week randomized, placebo-controlled, double-blind trial
A 10-week, randomized, placebo-controlled, double-blind trial evaluated the effects of nicotinamide mononucleotide (NMN) supplementation on metabolic function in overweight or obese postmenopausal women with prediabetes. Insulin-stimulated glucose disposal, evaluated using a hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling (AKT and mTOR phosphorylation) increased after NMN supplementation but did not change after placebo. Additionally, NMN supplementation up-regulated platelet-derived growth factor receptor β and other genes involved in muscle remodeling.
Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021. PMID 33888596
2021 / Double-blind, randomized, placebo-controlled trial
A double-blind, placebo-controlled trial evaluated daily supplementation with a fruit and vegetable concentrate (FVC) and high-fiber component across 57 pre-menopausal, overweight/obese female healthcare workers over five months. FVC supplementation had no effect on blood lipids, glucose, or immune parameters, but improved glucose clearance. FVC did not alter phyla-level taxonomy or alpha/beta diversity, but reduced Bacteroides abundance and increased fecal butyrate; adding a high-fiber component improved levels of health-associated bacteria.
van der Merwe M, Moore D, Hill JL, et al. Microorganisms, 2021. PMID 33920059
2020 / Single-blinded randomized pilot study
Forty participants with type 2 diabetes mellitus were randomized to 3 months of either yoga (postures and breathing exercises, n = 20) or sham yoga (nonaerobic stretching, n = 20). Both groups demonstrated significant within-group improvements in malondialdehyde, vitamin C, superoxide dismutase, fasting blood glucose, glycosylated hemoglobin, body mass index, waist circumference, and blood pressure. Yoga participants showed significantly greater improvement in reduced glutathione compared to controls, but no other significant differences between groups were observed.
Hegde SV, Adhikari P, Kotian SM, et al. Int J Yoga Therap, 2020. PMID 31283365
2020 / Randomized, placebo-controlled clinical trial
In a randomized, placebo-controlled trial, 40 middle-aged, obese, insulin-resistant men received 1000 mg nicotinamide riboside (NR) or placebo twice daily for 12 weeks. NR supplementation decreased NAMPT protein levels in skeletal muscle by 14%, but steady-state NAD+ levels and other biosynthetic enzymes were unchanged. NR did not affect skeletal muscle mitochondrial respiratory capacity, mitochondrial-associated protein abundance, mitochondrial fractional area, or network morphology.
Dollerup OL, Chubanava S, Agerholm M, et al. J Physiol, 2020. PMID 31710095
2020 / Double-blind, randomized crossover trial
In two study parts, healthy lean men received intragastric quinine (275 mg or 600 mg) or control 30 minutes before a mixed-nutrient drink (part A, n=15) or a buffet meal (part B, n=12). Alone, both doses modestly stimulated insulin (P < 0.05). Following the drink, both quinine doses reduced plasma glucose and stimulated insulin (P < 0.05); 275 mg stimulated GLP-1 (P < 0.05), while 600 mg showed a trend toward stimulating GLP-1 (P = 0.066) and glucagon (P = 0.073). Quinine did not alter gastric emptying of the nutrient drink or subsequent buffet energy intake.
Bitarafan V, Fitzgerald PCE, Little TJ, et al. Am J Physiol Regul Integr Comp Physiol, 2020. PMID 31774306
2020 / Crossover feeding trial
Thirteen healthy young men consumed a control diet for 2 weeks followed by 5 days of an isocaloric high-fat diet (HFD; 55% fat, 25% saturated). Intestinal permeability and responses to a high-fat meal challenge were evaluated before and after the HFD. Intestinal permeability was not affected by the HFD (p > 0.05), but fasting endotoxin increased two-fold (p = 0.04). Skeletal muscle glucose and fatty acid oxidation increased post-meal before the HFD (+97% and +106%) but decreased post-meal after the HFD (-24% and +16%, respectively), while insulin sensitivity remained unchanged.
Bowser SM, McMillan RP, Boutagy NE, et al. Metabolism, 2020. PMID 31785256
2020 / Randomized double-blind placebo-controlled pilot trial
In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.
Yu EW, Gao L, Stastka P, et al. PLoS Med, 2020. PMID 32150549
2020 / Randomized, double-blinded, placebo-controlled, crossover trial
In a randomized, double-blinded, placebo-controlled crossover study, 13 healthy overweight or obese adults received 1000 mg/d nicotinamide riboside (NR) and placebo for 6 weeks each. NR increased skeletal muscle markers of NAD+ synthesis, body fat-free mass (62.65% ± 2.49% vs 61.32% ± 2.58%; change: 1.34% ± 0.50%, P = 0.02), and sleeping metabolic rate. Skeletal muscle acetylcarnitine concentrations increased (4558 ± 749 vs 3025 ± 316 pmol/mg dry weight; change: 1533 ± 683, P = 0.04), along with exercise acetylcarnitine-forming capacity (P = 0.01). However, NR had no effects on insulin sensitivity, mitochondrial function, hepatic/intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, blood pressure, inflammation markers, or energy metabolism.
Remie CME, Roumans KHM, Moonen MPB, et al. Am J Clin Nutr, 2020. PMID 32320006
2020 / Two-period randomized crossover trial
In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.
Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313
2020 / Randomized, placebo-controlled study
Participants were randomized to wear a novel nasal device for 5-12 hours daily or receive daily saline nasal drops, alongside a 500 kcal/day reduced diet for 12 weeks. Sense of smell decreased from 6.4 ± 0.9 to 4.4 ± 1.5 in the device group (p < 0.001) with no change in controls. Overall weight loss was 6.6 ± 3.7% in the device group versus 5.7 ± 3.5% in controls (between-group p > 0.05), but was significantly greater with the device among participants aged ≤50 years (7.7 ± 4.2% vs. 4.1 ± 2.9%, p = 0.02). The device group also showed significant reductions in insulin, HOMA-IR, and preferences for sugar, sweet beverages, and artificial sweeteners.
Dicker D, Beck A, Markel A, et al. Obes Facts, 2020. PMID 32950989
2020 / Three-phase sequential intervention study
Thirty adolescents with type 1 diabetes completed three 1-week phases: Phase I with a standard diet, followed by Phase II adding oat flakes with 3 g/day beta-glucan, and Phase III adding oat flakes with 6 g/day beta-glucan. Maximal, mean, daytime, and night blood glucose levels were lowest at Phase III, while minimal blood glucose was highest at Phase III (p < 0.05). Premeal, postmeal, and peak blood glucose values were lowest at Phase III for breakfast, lunch, and overall, with delayed peak times (p < 0.05). Phase III also significantly reduced glycemic variability metrics including SD, CV, LBGI, and CONGA compared to Phase I or II (p < 0.05), while durations in hypoglycemia, euglycemia, and hyperglycemia did not differ significantly between phases.
Bozbulut R, Şanlıer N, Döğer E, et al. Diabetes Res Clin Pract, 2020. PMID 32971156
2019 / Crossover trial
Researchers evaluated postprandial glucose and insulin responses to an oral glucose tolerance test (OGTT at 0800h vs 2000h, n=10) and a low GI meal consumed at 0800h, 2000h, and 0000h (n=9). In the OGTT, glucose iAUC was higher in the evening than morning (p=0.007). Following the low GI meal, glucose iAUC was higher at evening and midnight compared to morning (p=0.008, p=0.021), with no significant difference between evening and midnight (p=0.594). Insulin iAUC was also significantly higher at evening and midnight compared to morning (p=0.008 for both).
Leung GKW, Huggins CE, Bonham MP Clin Nutr, 2019. PMID 29248250
2019 / Randomized open-label crossover trial
Fifteen patients with uncontrolled type 2 diabetes participated in a randomized, open-label crossover study receiving either two days of oatmeal or a diabetes-adapted diet during a 5-day hospital stay. Oatmeal significantly reduced required insulin doses on days 3 and 4 compared to day 2 (82.0±30.3 and 69.9±29.9 IU vs. 112±36.2 IU; P<0.001), whereas insulin requirements did not change during the control period. Mean blood glucose and fasting glucose changes did not differ significantly between treatments, but HbA1c was lower four weeks after the oatmeal intervention.
Delgado G, Kleber ME, Krämer BK, et al. Exp Clin Endocrinol Diabetes, 2019. PMID 30157531
2019 / Multicenter, randomized, double-blind, placebo-controlled trial
A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).
Bhatt DL, Steg PG, Miller M, et al. N Engl J Med, 2019. PMID 30415628